Biogen revenue and financials

BIIB · NASDAQ · USD

$222.89−0.31%−$0.70

Close · October 6, 2026

In the fiscal year ended December 2025, Biogen reported revenue of $9.89B (+2.22% year over year). Net income was $1.29B, a net margin of 13.1%.

Annual revenue · 2025: $9.89B

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total revenue	2,736	2,478	2,279	2,535	2,646	2,431	2,455	2,466	2,465	2,291	2,386	2,530
Cost of revenue	612	610	443	509	553	578	539	590	956	498	618	660
Gross profit	2,124	1,868	1,836	2,026	2,093	1,853	1,916	1,876	1,509	1,792	1,768	1,871
Selling, general and administrative	710	607	685	593	584	573	680	578	550	578	608	753
Research and development	492	482	477	432	399	434	506	507	—	438	568	736
Operating income	686	567	472	779	908	677	561	611	810	632	461	271
EBIT	686	567	472	779	908	677	561	611	810	632	461	271
EBITDA	922	772	672	981	1,102	860	745	794	968	780	601	396
Interest expense	82.3	67.6	67.5	67.4	72.6	60.0	60.0	59.8	61.3	69.2	71.5	63.8
Pre-tax income	132	378	-56.0	557	744	311	292	451	699	465	292	-141
Income tax	34.9	58.2	-7.1	90.8	109	70.7	24.8	62.5	115	71.4	42.7	-72.9
Net income	97.5	320	-48.9	467	635	241	267	389	584	393	250	-68.1
Net income to common shareholders	97.5	320	-48.9	467	635	241	267	389	584	393	250	-68.1
Basic EPS	0.66	2.17	-0.33	3.18	4.33	1.65	1.83	2.67	4.01	2.71	1.72	-0.47
Diluted EPS	0.66	2.15	-0.33	3.17	4.33	1.64	1.82	2.66	4.00	2.70	1.71	-0.47
Average shares (basic)	148	147	147	147	147	146	146	146	146	145	145	145
Average shares (diluted)	149	148	147	147	147	147	146	146	146	146	146	145